Trial Profile
Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine Versus Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Administered as Booster Doses to Healthy Children 4-6 Years, Each Co-administered With Merck's MMR Vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 01 Apr 2008 Primary endpoint 'Immunological response rate' has been met.
- 07 May 2007 Results were presented at the Pediatric Academic Societies (PAS) annual meeting.
- 05 Nov 2005 New trial record.